Benoit Pinteur

Brenus Pharma SAS is a French company that has developed an allogeneic platform to generate first in class immune therapy to prevent cancer resistance over treatment. The company is based in Issoire, France. The company's technology, stc10-10, targets mss and msi-h population with a robust and validated preclinical data pack to offer an off-the-shelf technology allowing control of both time and cost of the manufacturing process. Brenus Pharma aims to harness a specific, highly potent, and durable immune response against moving targets in cancer by claiming the representativity, the antigenicity, and the immunogenicity of its solution. The company was founded by Benoit Pinteur, Jacques Gardette. The CEO is Paul Bravetti.

Brenus Pharma SAS is a French company that has developed an allogeneic platform to generate first in class immune therapy to prevent cancer resistance over treatment. The company is based in Issoire, France. The company's technology, stc10-10, targets mss and msi-h population with a robust and validated preclinical data pack to offer an off-the-shelf technology allowing control of both time and cost of the manufacturing process. Brenus Pharma aims to harness a specific, highly potent, and durable immune response against moving targets in cancer by claiming the representativity, the antigenicity, and the immunogenicity of its solution. The company was founded by Benoit Pinteur, Jacques Gardette. The CEO is Paul Bravetti.